© 2021 MJH Life Sciences and Consultant Live. All rights reserved.
December 24, 2019
The oral CGRP antagonist becomes the first in its class approved for the indication.
December 23, 2019
The small molecule orexin receptor antagonist will be made available for the US market in 2 different doses, in 2020.
December 13, 2019
The approval comes 4 months following a Complete Response Letter was submitted and successfully disputed, to Sarepta Therapeutics.
October 25, 2019
The FDA approves Botox injections to treat pediatric patients with both upper and lower limb spasticity, unless it was caused by cerebral palsy.